Saturday, September 23, 2023
Saturday, September 23, 2023

AXA IM Alts Launches $500 Mil Private Equity Healthcare Strategy Alongside 2 Senior Appointments

AXA IM Alts, a global leader in alternative investments with c. €183 billion[3] of assets under management, announces the launch of a Global Health Strategy (the ‘Strategy’) following a $200 million (c. €181 million) cornerstone commitment from AXA Group[4], as it builds on its existing offering in the sector. The Strategy is actively managed without reference to any benchmark.

The Strategy focuses specifically on four core areas of innovation: medical devices, biopharmaceuticals, vaccines, and diagnostics and on investments into healthcare companies that are in late-clinical and/or early commercial stages, which represent a key inflection point of a company’s organic growth trajectory.

Targeting total commitments of up to $500 million (over €440 million), the Strategy seeks investments in companies aiming to deliver healthcare solutions at accessible price points for global markets, including high volume markets, where demand for new products continues to benefit from rapid growth in healthcare spending and population growth. Global healthcare spending grew 30% faster than global GDP from 2010 to 2017, with the rate twice as fast in middle income versus high income economies[5]. Additionally, there is a significant funding gap in global healthcare, further fuelling investment opportunities and the potential for attractive relative value.

Alongside this announcement, AXA IM Alts is pleased to share that it has appointed two new Partners to lead the Strategy – Curt LaBelle and Zina Affas Besse as Head and Deputy Head of Healthcare Private Equity, respectively, as a natural continuation of its existing private equity healthcare expertise. Each with over 20 years’ experience within healthcare and investing, Curt and Zina bring a wealth of experience and strong track record in investing, advising, and operating in healthcare start-ups globally, including running Global Health Investment Advisors (“GHIA”), a US-based investment manager focused on global health since 2015.

The appointments are the fruition of a long-standing relationship which was established in 2013 and has seen AXA IM Alts work alongside GHIA on multiple transactions in the global health sector. This includes participation in the design, portfolio construction and investment execution of the existing global healthcare strategy, and most recently the successful exit from Alydia Health[7] in 2021. The launch of this Strategy is the natural continuation of this successful collaboration as AXA IM Alts seeks to deliver healthcare investment opportunities at scale and further build its private equity franchise.

Curt and Zina join Alexandre Martin-Min, Managing Partner, CIO Structured Finance and Impact Private Equity and Jonathan Dean, Partner, Head of Fund Management Impact Private Equity at AXA IM Alts who are responsible for the impact investing platforms. This group forms the investment committee leading the newly launched Global Health Strategy.

AXA IM Alts believes that investing in and filling the funding gap in this segment of the market offers an opportunity for enhanced value creation, particularly when combined with its hands-on approach to engagement with investee companies. The high-volume markets targeted by the Strategy will allow for significant and measurable impact at scale through the investments made, promoting global solutions to global health challenges. As such, and building off AXA IM Alts’ deep impact investing expertise, the Strategy will be aligned to the United Nations Sustainable Development Goals (SDGs)[6] and directly contribute to broader impact objectives of AXA IM Alts and of the investors in this strategy.

The Strategy benefits from AXA IM Alts’ significant private equity franchise, which is one of its fastest growing investment platforms, with already €8bn in assets under management, and which is able to leverage the broader expertise of the AXA IM Alts’ Impact, Structured Finance and Real Assets teams, taking a ‘360 approach’ and accessing investments directly and indirectly through equity and debt. Healthcare is a key pillar throughout AXA IM Alts’ platform, with landmark deals including Kadans Science Parks, a fully integrated developer, owner and operator of European science parks and lab offices, and most recently of Amedes, a leading provider of medical diagnostics services in Germany, Belgium and Austria[8]. As such, AXA IM Alts healthcare private equity benefits from a wide access to an extended network and expertise in the healthcare ecosystem.

Alexandre Martin-Min, Managing Partner, CIO of Structured Finance and Impact Private Equity at AXA IM Alts commented:

“As a long-term investor across healthcare markets we, at AXA IM Alts, have observed a large funding gap when it comes to certain areas within private equity markets, which has led to the development of this opportunity. Through this Strategy we invest in companies that deliver products and services that are profitable at accessible price points by addressing high volume markets, as opposed to only the high-income customers that private capital is traditionally limited to. The launch of this Strategy further supports our commitment of bringing our clients highly diversified, impact-driven solutions at scale that capitalise on market trends.”

Curt LaBelle, Partner, Head of Healthcare Private Equity at AXA IM Alts commented: “With a combined 40 years of experience investing and working in the healthcare sector, Zina and I are thrilled to utilise our deep background and strong track record to build upon AXA IM Alts unparalleled expertise to drive the new Strategy. Having led investments in 30 deals, worked on 20 boards, produced strong financial returns and achieved over 30 product approvals throughout devices, diagnostics, vaccines, pharmaceuticals and services, I am excited to leverage my background and expertise to inform investment decisions within the new Strategy. Building on our longstanding relationship with AXA IM Alts, we recognise the strong benefits of its long history in healthcare, private equity, impact and thematic investing, as well as its fully integrated alternatives investment platform. Having worked with the team for years, our strong convictions will allow us to pursue this market opportunity at scale, whilst improving lives globally and delivering performance outcomes to our clients.”


1.Curt LaBelle holds a dual Medical Degree (MD) and MBA from Columbia University Vagelos College of Physicians and Surgeons and Columbia Business School respectively (1999)

  1. Zina Affas Besse holds a PhD in Medicinal Chemistry (1999) and a BPharm (Hons) in Pharmacy (1994) from the University of Nottingham.
  2. Source: AXA IM Alts unaudited data, as of December 2021
  3. Source : – March 2022.
  4. Source: World Health Organization as of October 2021
    6. Addressing SDGs 3, 5 & 10
  5. There is no assurance that a similar level of exit will be achieved for any future investment in the Global Health Strategy
    8. Companies shown are for illustrative purposes only and may no longer be in the portfolio later. It should not be considered a recommendation to purchase or sell any security.
Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.


Carthera Appoints Dr Oern Stuge as Chairman of Board of Directors

Dr Oern Stuge brings 30+ years expertise with a wealth of experience in product development and commercial launches to support Carthera’s future growth.

Cytomos Appoints a New Director as £4 Mill Investment Sets Path for Commercialisation of Groundbreaking Cell Analysis Technology

The biotech company’s appointment of industry leader Dr Sharon Brownlow as Non-Executive Director further enhances Cytomos’ senior management team and its unique value proposition to key industry markets.

Kindeva Drug Delivery Appoints Brian Schubmehl as Chief Human Resources Officer

Brian Schubmehl brings more than two decades of diverse and senior global leadership expertise that has spanned private equity, startup, and publicly traded organizations.

Joseph Schwab MD, MS, to Lead Spine-Oncology Program and Center for Surgical Technology and AI Research at Cedars-Sinai

Joseph Schwab combines extensive experience in translational research and clinical trials with a record of high-quality clinical care. He specializes in the management of benign and malignant bone tumors as well as spinal disorders, including stenoses and myelopathy. His expertise will drive transformative advancements in spine oncology and surgical technology at Cedars-Sinai.

Perimeter Medical Imaging AI Strengthens Leadership Team with Appointment of Experienced MedTech Executive, Adam Hodges, as Vice President, Sales and Marketing

Adam Hodges brings more than 20 years of commercialization experience in the medical device industry. Most recently, Adam was Vice President of Sales at SIA Health, leading the commercial acceleration of DuraSorb®, which was acquired by Integra LifeSciences (NASDAQ: IART) in December 2022. During his tenure at SIA, Adam grew sales revenue by more than 5X in less than two years and previously served concurrent roles of Vice President of Strategic Accounts and Regional Business Director.

By using this website you agree to accept Medical Device News Magazine Privacy Policy